Trial record 1 of 1 for:    NCT01921426
Previous Study | Return to List | Next Study

A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Galera Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT01921426
First received: August 8, 2013
Last updated: July 16, 2015
Last verified: July 2015
  Purpose

The purpose of this study is to determine the safety, tolerability, and the highest dose of GC4419 that can be given to patients with squamous cell cancer of the head and neck who are receiving standard radiation therapy and chemotherapy. This study will also evaluate GC4419 for the following:

  • Effect on the incidence and severity of radiation induced oral mucositis;
  • Effect on the response rate of squamous cell cancer of the head and neck who are receiving radiation therapy and chemotherapy;
  • Total concentrations of GC4419 that can be achieved in the blood;
  • Changes in proteins and genetics associated with oral mucositis;
  • Impact on delayed toxicities of radiation (dry mouth and reduced ability to fully open the mouth);
  • Observe changes in genetic and molecular markers of oral mucositis;
  • Observe the usage of extra health resources (e.g., unplanned ER visits, feeding tube use, etc.) of study patients;
  • Assess the overall quality of life in study patients with oral mucositis.

Condition Intervention Phase
Squamous Cell Carcinoma of the Oral Cavity
Squamous Cell Carcinoma of the Oropharynx
Drug: GC4419
Phase 1

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Supportive Care
Official Title: A Phase 1 Dose Escalation Study of GC4419 in Combination With Radiation and Chemotherapy for Squamous Cell Cancers of the Head and Neck.

Resource links provided by NLM:


Further study details as provided by Galera Therapeutics, Inc.:

Primary Outcome Measures:
  • Frequency and Severity of Adverse Events Resulting from GC4419 [ Time Frame: 14 - 35 days ] [ Designated as safety issue: Yes ]
    GC4419 will be evaluated to determine safety, tolerability, and the maximum tolerated dose of GC4419 that can be administered to patients with squamous cell cancer of the head and neck who are receiving concurrent radiation (50-70 Gy, administered daily x 5 [M-F], in 2.0-2.2 Gy fractions) and chemotherapy (cisplatin, 80-100mg/m2, q3 weeks or weekly cisplatin 30-40mg/m2 x 6 weeks). Patients will receive 14 - 35 doses of GC4419 in serially ascending cohorts for dose and duration, which correspond to the first doses of radiation, schedule dependent. Dose limiting toxicity will be evaluated through 24 hours following the last dose of GC4419.


Secondary Outcome Measures:
  • Rate and Extent of Exposure to GC4419 (Pharmacokinetic Profile) [ Time Frame: 18 - 49 Days ] [ Designated as safety issue: Yes ]
    Determine the pharmacokinetic profile, including the extent and rate of exposure (e.g., maximum concentration, total exposure, half life, time to maximum concentration, accumulation, etc.) to GC4419, as well as GC4419 kinetics (e.g., half-life, in patients with squamous cell carcinoma of the head and neck receiving GC4419 when administered in combination with standard chemoradiation.

  • Oral Mucositis [ Time Frame: 49 Days ] [ Designated as safety issue: Yes ]
    Determine the incidence, severity, time to first onset and duration of oral mucositis in patients with squamous cell carcinoma of the head and neck receiving GC4419 when administered in combination with standard chemoradiation.

  • Antitumor Effect [ Time Frame: 14 Months ] [ Designated as safety issue: No ]
    Preliminarily assess the tumor response to standard chemoradiation when administered in conjunction with GC4419 at approximately 1 year following completion of chemoradiation.


Other Outcome Measures:
  • Pharmacodynamic Profile [ Time Frame: 49 Days ] [ Designated as safety issue: No ]
    Determine the pharmacodynamic profile of GC4419 in patients with squamous cell carcinoma of the head and neck receiving GC4419 when administered in combination with standard chemoradiation by observing the changes in proteins and genetic markers associated oral mucositis.


Estimated Enrollment: 30
Study Start Date: August 2013
Estimated Study Completion Date: July 2016
Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: GC4419
Open label, dose escalation study of GC4419 administered in 14 doses, corresponding to the first 14 doses of radiation therapy. Each dose will be given intravenously over 60 minutes. The possible doses which may be tested are: 15mg, 30mg, 50mg, 75mg, 112mg, and 170mg.
Drug: GC4419

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Pathologically-confirmed diagnosis of squamous cell carcinoma of the head and neck (SCCHN), defined as SCC of the oral cavity or oropharynx, that will be treated with standard cisplatin and Intensity-Modulated Radiation Therapy (IMRT)
  • Males or females aged 18 years or older
  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
  • Adequate bone marrow, liver and kidney function
  • Negative serum pregnancy test for females of childbearing potential
  • Properly obtained written informed consent

Exclusion Criteria:

  • Tumor of the lips, larynx, hypopharynx, nasopharynx, sinuses, salivary glands or unknown primary tumor
  • Metastatic disease (Stage IV C)
  • Prior chemotherapy for SCCHN and/or radiotherapy to the region of the study cancer or
  • Receiving any agent classified as an antioxidant
  • History of malignant tumors other than SCCHN within the last 5 years, except non-melanoma skin cancer or curatively excised in situ cervical carcinoma
  • Active infectious disease excluding oral candidiasis
  • Presence of oral mucositis at study entry
  • Chronic immunosuppression
  • Known history of HIV or active hepatitis B/C )
  • Prior history of hearing impairment
  • Use of investigational agent within 30 days of study entry
  • Known allergies or intolerance to cisplatin and similar platinum-containing compounds
  • Requirement for concurrent treatment with nitrates or other drugs that may, in the judgment of the treating investigator, create a risk for a precipitous decrease in blood pressure
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01921426

Locations
United States, Florida
Lakeland Regional Cancer Center
Lakeland, Florida, United States, 33805
United States, Iowa
University of Iowa
Iowa City, Iowa, United States, 52242
United States, Missouri
Washington University School of Medicine
St. Louis, Missouri, United States, 63110
United States, Nebraska
University of Nebraska Medical Center
Omaha, Nebraska, United States, 68198
United States, New York
University of Rochester Medical Center
Rochester, New York, United States, 14642
United States, North Carolina
Wake Forest Baptist Health
Winston-Salem, North Carolina, United States, 27157
United States, Ohio
Summa Health System- Cooper Cancer Center
Akron, Ohio, United States, 44304
United States, Pennsylvania
St. Luke's Cancer Center
Easton, Pennsylvania, United States, 18045
Allegheny General Hospital
Pittsburgh, Pennsylvania, United States, 15212
United States, Washington
Cancer Care Northwest
Spokane, Washington, United States, 99216
Sponsors and Collaborators
Galera Therapeutics, Inc.
Investigators
Study Director: Jon T. Holmlund, MD Galera Therapeutics, Inc.
Principal Investigator: Madhavi Venigalla, MD Lakeland Regional Cancer Center
Principal Investigator: Weining Zhen, MD University of Nebraska
Principal Investigator: Douglas Adkins, MD Washington University School of Medicine
Principal Investigator: Pardip Pathare, MD Norwalk Hospital
Principal Investigator: Sanjiv Agarwala, MD St. Luke's Cancer Center
Principal Investigator: Charles Kunos, MD, PhD Summa Health System- Cooper Cancer Center
Principal Investigator: Yuhchyau Chen, MD, PhD University of Rochester
Principal Investigator: John Buatti, MD University of Iowa
Principal Investigator: Aftab Mahmood, MD Cancer Specialists of South Texas, P.A.
Principal Investigator: Larisa Greenberg, MD West Penn Allegheny Health System
Principal Investigator: Marcelo Bonomi, MD Wake Forest Baptist Health
Principal Investigator: Christopher M Lee, MD Cancer Care Northwest
  More Information

No publications provided

Responsible Party: Galera Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT01921426     History of Changes
Other Study ID Numbers: GT-001
Study First Received: August 8, 2013
Last Updated: July 16, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by Galera Therapeutics, Inc.:
Squamous Cell Carcinoma of the Head and Neck
Oral Cavity
Oropharynx
Radiation
Chemotherapy
Cisplatin
Oral Mucositis
Superoxide Dismutase

Additional relevant MeSH terms:
Carcinoma
Carcinoma, Squamous Cell
Oropharyngeal Neoplasms
Head and Neck Neoplasms
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Neoplasms, Squamous Cell
Otorhinolaryngologic Diseases
Otorhinolaryngologic Neoplasms
Pharyngeal Diseases
Pharyngeal Neoplasms
Stomatognathic Diseases

ClinicalTrials.gov processed this record on July 30, 2015